Validation period: 10/7/2022, 5:13:34 PM - 10/7/2022, 11:13:34 PM
BMJ Journals logo
Email alerts

The Journal for ImmunoTherapy of Cancer

is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.

Impact Factor: 12.469
Citescore: 14.3
All metrics >>

The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

JITC is the official journal of the Society for Immunotherapy of Cancer (SITC).

EDITOR-IN-CHIEF
Pedro J. Romero, MD, University of Lausanne
Editorial Board

Current IssueJournal Current Issue

Highlighted Articles

Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors

Authors

The Journal for ImmunoTherapy of Cancer accepts a variety of article types in a number of formats.

The Author Information section provides specific article requirements and section outlines to help you turn your research into an article suitable for JITC.

Information is also provided on editorial policy, Open Access fees and formatting.

A guide to publishing in JITC

Author informationSubmit a paper

Twitter Feed

COVID-19 and Cancer Immunotherapy

Review:

JAK inhibitors and COVID-19

22 April 2022

Latest Articles

Altmetrics

altmetric badge
Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner
7 February 2022

What Our Editors Are Reading

In JITC’s Reading List, JITC editors provide a monthly list of publications in other journals that have their attention and add value to what readers may find in JITC. Read what has piqued the interest of this month’s featured editor in the latest Reading List.

JITC Reading List

About SITC

SITC Society Logo
The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

Explore SITC’s cancer immunotherapy community at sitcancer.org and become a member to take advantage of SITC’s member benefit of 50% off APCs for all articles submitted and accepted in JITC in 2022.

SITC Society Logo
CONTENT
  • Latest content
  • Browse by collection
  • Archive
  • Top cited articles
rss-icontwitter-icon
bmj-footer-logo
Website Terms & ConditionsPrivacy & CookiesContact BMJCookie settingsOnline ISSN: 2051-1426Copyright © 2022 BMJ Publishing Group Ltd and Society for Immunotherapy of Cancer. All rights reserved.